Federal Circuit affirms district court finding of no induced or contributory infringement of generic depression drug
Allen & Overy » Life Sciences
by
1w ago
In H. Lundbeck A-S v. Lupin Ltd., Case No. 2022-1194 (Fed. Circ. December 7, 2023), Plaintiffs, H. Lundbeck A/S (“Lundbeck”) and Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A ..read more
Visit website
EU publishes summary of recent competition enforcement in the pharmaceutical sector and promises to continue policy of proactive enforcement
Allen & Overy » Life Sciences
by
2w ago
The European Commission (EC) has published its latest report on competition enforcement in medicines and medical products.  ..read more
Visit website
Senate Bill Introduced to Examine Bayh-Dole Reporting Requirements
Allen & Overy » Life Sciences
by
1M ago
On January 10, 2024, Senators Chris Coons and Thom Tillis introduced a bill titled Improving Efficiency to Increase Competition Act (“IEICA”).  The IEICA would require that the Comptroller General ..read more
Visit website
Medical Devices: Find your path through the regulatory jungle
Allen & Overy » Life Sciences
by
1M ago
In Germany and the EU, medical devices are subject to a complex and evolving regulatory framework, covering aspects such as safety, performance, clinical evaluation, labelling, post-marketing ..read more
Visit website
Biden Administration Releases New Proposed Framework for the Exercise of “March-In” Rights under Bayh-Dole
Allen & Overy » Life Sciences
by
2M ago
The Biden Administration’s recent publication of the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights and its request for comments on the draft guidance will impact ..read more
Visit website
European Commission sanctions first ever pharmaceuticals cartel and scores victory in pay-for-delay appeal
Allen & Overy » Life Sciences
by
3M ago
The European Commission (EC) has fined five pharmaceutical companies a total of EUR13.4 million for participating in a cartel concerning N-Butylbromide Scopolamine/Hyoscine (SNBB) – an active ..read more
Visit website
UK CMA issues 'prioritisation statement' to allay competition law fears that prevent combination therapies reaching NHS
Allen & Overy » Life Sciences
by
3M ago
The UK Competition and Markets Authority (CMA) has taken the unusual step of issuing a prioritisation statement on cooperation between competitors to make combination therapies available to the NHS ..read more
Visit website
European Commission sanctions first ever pharmaceuticals cartel and scores victory in pay-for-delay appeal
Allen & Overy » Life Sciences
by
4M ago
The European Commission (EC) has fined five pharmaceutical companies a total of EUR13.4 million for participating in a cartel concerning N-Butylbromide Scopolamine/Hyoscine (SNBB) – an active ..read more
Visit website
Webinar: Managing supply chain risk in the life sciences sector
Allen & Overy » Life Sciences
by
4M ago
In increasingly complex and uncertain economic times, companies in the life sciences sector are facing unique supply chain challenges ..read more
Visit website
HHS selects the first drugs for Medicare drug price negotiation
Allen & Overy » Life Sciences
by
4M ago
On August 29, 2023, Health and Human Services (“HHS”) announced the first ten drugs covered by Medicare Part D selected for negotiation under President Biden’s Inflation Reduction Act of 2022 (“IRA ..read more
Visit website

Follow Allen & Overy » Life Sciences on FeedSpot

Continue with Google
Continue with Apple
OR